IL315814A - Crystalline forms of immunomodulators - Google Patents
Crystalline forms of immunomodulatorsInfo
- Publication number
- IL315814A IL315814A IL315814A IL31581424A IL315814A IL 315814 A IL315814 A IL 315814A IL 315814 A IL315814 A IL 315814A IL 31581424 A IL31581424 A IL 31581424A IL 315814 A IL315814 A IL 315814A
- Authority
- IL
- Israel
- Prior art keywords
- compound
- formula
- mixture
- solution
- solvent
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2017/104485 WO2019061324A1 (en) | 2017-09-29 | 2017-09-29 | CRYSTALLINE FORMS OF IMMUNOMODULATORS |
| PCT/US2018/053052 WO2019067678A1 (en) | 2017-09-29 | 2018-09-27 | CRYSTALLINE FORMS OF IMMUNOMODULATORS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL315814A true IL315814A (en) | 2024-11-01 |
Family
ID=65900346
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL315814A IL315814A (en) | 2017-09-29 | 2018-09-27 | Crystalline forms of immunomodulators |
| IL273463A IL273463A (en) | 2017-09-29 | 2020-03-19 | Crystalline forms of immunomodulators |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL273463A IL273463A (en) | 2017-09-29 | 2020-03-19 | Crystalline forms of immunomodulators |
Country Status (14)
| Country | Link |
|---|---|
| US (5) | US11040948B2 (https=) |
| EP (1) | EP3687534A4 (https=) |
| JP (2) | JP7783688B2 (https=) |
| KR (2) | KR20240115921A (https=) |
| CN (2) | CN111163772A (https=) |
| AU (2) | AU2018341583B2 (https=) |
| BR (1) | BR112020006137A2 (https=) |
| CA (1) | CA3076013A1 (https=) |
| EA (1) | EA202090500A1 (https=) |
| IL (2) | IL315814A (https=) |
| MY (1) | MY201378A (https=) |
| PH (1) | PH12020550133A1 (https=) |
| SG (1) | SG11202002378XA (https=) |
| WO (2) | WO2019061324A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE038169T2 (hu) | 2013-09-06 | 2018-09-28 | Aurigene Discovery Tech Ltd | 1,2,4-Oxadiazol származékok mint immunomodulátorok |
| KR102894264B1 (ko) | 2015-03-10 | 2025-12-02 | 오리진 온콜로지 리미티드 | 면역조절제로서의 1,2,4-옥사다이아졸 및 티아다이아졸 화합물 |
| WO2019061324A1 (en) | 2017-09-29 | 2019-04-04 | Curis Inc. | CRYSTALLINE FORMS OF IMMUNOMODULATORS |
| EP3694841A1 (en) | 2017-10-11 | 2020-08-19 | Aurigene Discovery Technologies Limited | Crystalline forms of 3-substituted 1,2,4-oxadiazole |
| MY206121A (en) | 2017-11-03 | 2024-11-29 | Aurigene Discovery Tech Ltd | Dual inhibitors of tim-3 and pd-1 pathways |
| AU2018360389B2 (en) | 2017-11-06 | 2024-09-19 | Aurigene Oncology Limited | Conjoint therapies for immunomodulation |
| SG11202106250RA (en) | 2018-12-20 | 2021-07-29 | Impact Selector International Llc | Downhole tool for connecting with a conveyance line |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3227725A (en) | 1962-04-17 | 1966-01-04 | Union Carbide Corp | Certain 3,5-disubstituted 1,2,4-oxadiazole compounds |
| TW201311B (https=) | 1991-06-17 | 1993-03-01 | Hoffmann La Roche | |
| CA2143246C (en) | 1994-03-16 | 2000-08-22 | Thierry Godel | Imidazodiazepines |
| PL354286A1 (en) | 1999-08-23 | 2003-12-29 | Dana-Farber Cancer Institutedana-Farber Cancer Institute | Pd-1, a receptor for b7-4, and uses therefor |
| WO2002079499A1 (en) | 2001-04-02 | 2002-10-10 | Wyeth | Pd-1, a receptor for b7-4, and uses therefor |
| US7794710B2 (en) | 2001-04-20 | 2010-09-14 | Mayo Foundation For Medical Education And Research | Methods of enhancing T cell responsiveness |
| CA2466279A1 (en) | 2001-11-13 | 2003-05-22 | Dana-Farber Cancer Institute, Inc. | Agents that modulate immune cell activation and methods of use thereof |
| GB0204159D0 (en) | 2002-02-22 | 2002-04-10 | British Biotech Pharm | Metalloproteinase inhibitors |
| AU2003281200A1 (en) | 2002-07-03 | 2004-01-23 | Tasuku Honjo | Immunopotentiating compositions |
| CN101899114A (zh) | 2002-12-23 | 2010-12-01 | 惠氏公司 | 抗pd-1抗体及其用途 |
| TW200524601A (en) | 2003-12-05 | 2005-08-01 | Bristol Myers Squibb Co | Heterocyclic anti-migraine agents |
| US7585881B2 (en) | 2004-02-18 | 2009-09-08 | Astrazeneca Ab | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| EP1593671A1 (en) | 2004-03-05 | 2005-11-09 | Graffinity Pharmaceuticals AG | DPP-IV inhibitors |
| EP1838706A1 (en) | 2004-12-24 | 2007-10-03 | Prosidion Limited | G-protein coupled receptor agonists |
| DK2439273T3 (da) | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| EP1888512A2 (en) | 2005-06-06 | 2008-02-20 | Smithkline Beecham Corporation | Chemical compounds |
| US20090042926A1 (en) | 2005-12-20 | 2009-02-12 | Jason Imbriglio | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment |
| CN101484433A (zh) | 2006-02-15 | 2009-07-15 | 艾博特公司 | 新的乙酰辅酶a羧化酶(acc)抑制剂及其在糖尿病、肥胖症和代谢综合征中的应用 |
| AU2007275221A1 (en) | 2006-07-20 | 2008-01-24 | Allen J. Borchardt | Benzothiophene inhibitors of RHO kinase |
| PL2076501T3 (pl) * | 2006-09-25 | 2016-06-30 | Ptc Therapeutics Inc | Postacie krystaliczne kwasu 3-[5-(2-fluorofenylo)[1,2,4]oksadiazol-3-ilo]-benzoesowego |
| BR122017025062B8 (pt) | 2007-06-18 | 2021-07-27 | Merck Sharp & Dohme | anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento |
| WO2009006555A2 (en) | 2007-07-02 | 2009-01-08 | Yu, Ming | Methods, composition, targets for combinational cancer treatments |
| US7868001B2 (en) | 2007-11-02 | 2011-01-11 | Hutchison Medipharma Enterprises Limited | Cytokine inhibitors |
| EA018551B1 (ru) | 2008-02-22 | 2013-08-30 | Айрм Ллк | ГЕТЕРОЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ И СОДЕРЖАЩИЕ ИХ КОМПОЗИЦИИ В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗ c-KIT И PDGFR |
| WO2010033701A2 (en) | 2008-09-19 | 2010-03-25 | Genzyme Corporation | Inhibitors of sphingosine kinase 1 |
| JP2012507563A (ja) | 2008-10-30 | 2012-03-29 | エリクシアー ファーマシューティカルズ， インコーポレイテッド | スルホンアミド含有化合物およびその使用 |
| EP3255060A1 (en) | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| PL2504364T3 (pl) | 2009-11-24 | 2017-12-29 | Medimmune Limited | Ukierunkowane środki wiążące przeciwko B7-H1 |
| WO2011082400A2 (en) | 2010-01-04 | 2011-07-07 | President And Fellows Of Harvard College | Modulators of immunoinhibitory receptor pd-1, and methods of use thereof |
| WO2011137587A1 (en) | 2010-05-06 | 2011-11-10 | Hutchison Medipharma Limited | Cytokine inhibitors |
| US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| WO2012129564A2 (en) | 2011-03-24 | 2012-09-27 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Proteasome chymotrypsin-like inhibition using pi-1833 analogs |
| WO2012168944A1 (en) | 2011-06-08 | 2012-12-13 | Aurigene Discovery Technologies Limited | Therapeutic compounds for immunomodulation |
| BR112014007310A2 (pt) | 2011-09-27 | 2017-04-04 | Novartis Ag | 3-pirimidin-4-il-oxazolidin-2-onas como inibidores de idh mutante |
| WO2013132317A1 (en) | 2012-03-07 | 2013-09-12 | Aurigene Discovery Technologies Limited | Peptidomimetic compounds as immunomodulators |
| CA2868408A1 (en) | 2012-03-29 | 2013-10-03 | Aurigene Discovery Technologies Limited | Immunomodulating cyclic compounds from the bc loop of human pd1 |
| BR112015007672A2 (pt) | 2012-10-04 | 2017-08-08 | Dana Farber Cancer Inst Inc | anticorpos anti-pd-l1 monoclonais humanos e métodos de uso |
| AU2013329186B2 (en) | 2012-10-10 | 2019-02-14 | Sangamo Therapeutics, Inc. | T cell modifying compounds and uses thereof |
| AR093984A1 (es) | 2012-12-21 | 2015-07-01 | Merck Sharp & Dohme | Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano |
| US9220710B2 (en) | 2013-01-09 | 2015-12-29 | Gilead Sciences, Inc. | Therapeutic compounds |
| JP6387360B2 (ja) | 2013-03-14 | 2018-09-05 | ノバルティス アーゲー | 変異ｉｄｈの阻害薬としての３−ピリミジン−４−イル−オキサゾリジン−２−オン |
| WO2014147586A1 (en) | 2013-03-22 | 2014-09-25 | Novartis Ag | 1-(2-(ethylamino)pyrimidin-4-yl)pyrrolidin-2-ones as inhibitors of mutant idh |
| EA029661B1 (ru) * | 2013-09-06 | 2018-04-30 | Ауриген Дискавери Текнолоджиз Лимитед | Производные 1,3,4-оксадиазола и 1,3,4-тиадиазола в качестве иммуномодуляторов |
| HUE038169T2 (hu) | 2013-09-06 | 2018-09-28 | Aurigene Discovery Tech Ltd | 1,2,4-Oxadiazol származékok mint immunomodulátorok |
| CN112552401B (zh) | 2013-09-13 | 2023-08-25 | 广州百济神州生物制药有限公司 | 抗pd1抗体及其作为治疗剂与诊断剂的用途 |
| GB2516515B8 (en) | 2013-12-04 | 2016-10-05 | Intelligent Growth Solutions Ltd | Automated arrangement to grow plants under lighting in a vertical tower |
| US10174012B2 (en) * | 2014-11-04 | 2019-01-08 | The University Of Kansas | LKB1-AMPK activators for therapeutic use in polycystic kidney disease |
| BR112017019304A2 (pt) | 2015-03-10 | 2018-05-08 | Aurigene Discovery Technologies Limited | compostos de 1,2,4-oxadiazol 3-substituído e tiadiazol como imunomoduladores |
| KR102894264B1 (ko) | 2015-03-10 | 2025-12-02 | 오리진 온콜로지 리미티드 | 면역조절제로서의 1,2,4-옥사다이아졸 및 티아다이아졸 화합물 |
| EA201791629A1 (ru) | 2015-03-10 | 2018-02-28 | Ауриджен Дискавери Текнолоджис Лимитед | 1,3,4-оксадиазольные и тиадиазольные соединения в качестве иммуномодуляторов |
| GB201517217D0 (en) | 2015-09-29 | 2015-11-11 | Astex Therapeutics Ltd And Cancer Res Technology Ltd | Pharmaceutical compounds |
| PE20181326A1 (es) | 2015-11-03 | 2018-08-20 | Janssen Biotech Inc | Anticuerpos que se unen especificamente a pd-1 y sus usos |
| WO2018047143A1 (en) | 2016-09-12 | 2018-03-15 | Aurigene Discovery Technologies Limited | Vista signaling pathway inhibitory compounds useful as immunomodulators |
| WO2018051254A1 (en) | 2016-09-14 | 2018-03-22 | Aurigene Discovery Technologies Limited | Cyclic substituted-1,2,4-oxadiazole compounds as immunomodulators |
| AU2017345500B2 (en) | 2016-10-20 | 2022-03-10 | Aurigene Oncology Limited | Dual inhibitors of vista and PD-1 pathways |
| WO2019061324A1 (en) * | 2017-09-29 | 2019-04-04 | Curis Inc. | CRYSTALLINE FORMS OF IMMUNOMODULATORS |
| EP3694841A1 (en) | 2017-10-11 | 2020-08-19 | Aurigene Discovery Technologies Limited | Crystalline forms of 3-substituted 1,2,4-oxadiazole |
| MY206121A (en) | 2017-11-03 | 2024-11-29 | Aurigene Discovery Tech Ltd | Dual inhibitors of tim-3 and pd-1 pathways |
| AU2018360389B2 (en) | 2017-11-06 | 2024-09-19 | Aurigene Oncology Limited | Conjoint therapies for immunomodulation |
-
2017
- 2017-09-29 WO PCT/CN2017/104485 patent/WO2019061324A1/en not_active Ceased
-
2018
- 2018-09-27 IL IL315814A patent/IL315814A/en unknown
- 2018-09-27 JP JP2020517332A patent/JP7783688B2/ja active Active
- 2018-09-27 US US16/651,830 patent/US11040948B2/en active Active
- 2018-09-27 CN CN201880063100.5A patent/CN111163772A/zh active Pending
- 2018-09-27 WO PCT/US2018/053052 patent/WO2019067678A1/en not_active Ceased
- 2018-09-27 KR KR1020247023778A patent/KR20240115921A/ko active Pending
- 2018-09-27 EA EA202090500A patent/EA202090500A1/ru unknown
- 2018-09-27 CA CA3076013A patent/CA3076013A1/en active Pending
- 2018-09-27 BR BR112020006137-9A patent/BR112020006137A2/pt unknown
- 2018-09-27 CN CN202311171278.0A patent/CN117209444A/zh active Pending
- 2018-09-27 EP EP18863750.8A patent/EP3687534A4/en active Pending
- 2018-09-27 AU AU2018341583A patent/AU2018341583B2/en active Active
- 2018-09-27 SG SG11202002378XA patent/SG11202002378XA/en unknown
- 2018-09-27 MY MYPI2020001542A patent/MY201378A/en unknown
- 2018-09-27 KR KR1020207009251A patent/KR20200060402A/ko not_active Ceased
-
2020
- 2020-03-19 IL IL273463A patent/IL273463A/en unknown
- 2020-03-25 PH PH12020550133A patent/PH12020550133A1/en unknown
-
2021
- 2021-06-17 US US17/350,445 patent/US11643401B2/en active Active
-
2023
- 2023-01-25 US US18/101,387 patent/US11939306B2/en active Active
- 2023-06-30 JP JP2023108094A patent/JP2023134541A/ja active Pending
-
2024
- 2024-01-17 US US18/414,958 patent/US12252475B2/en active Active
- 2024-03-26 AU AU2024201938A patent/AU2024201938A1/en not_active Abandoned
-
2025
- 2025-02-13 US US19/052,863 patent/US20250188045A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3687534A1 (en) | 2020-08-05 |
| JP7783688B2 (ja) | 2025-12-10 |
| PH12020550133A1 (en) | 2021-02-08 |
| SG11202002378XA (en) | 2020-04-29 |
| US20200247766A1 (en) | 2020-08-06 |
| JP2021501127A (ja) | 2021-01-14 |
| US11040948B2 (en) | 2021-06-22 |
| US12252475B2 (en) | 2025-03-18 |
| EP3687534A4 (en) | 2021-06-30 |
| AU2024201938A1 (en) | 2024-04-11 |
| KR20240115921A (ko) | 2024-07-26 |
| AU2018341583A1 (en) | 2020-04-02 |
| US20250188045A1 (en) | 2025-06-12 |
| IL273463A (en) | 2020-05-31 |
| CA3076013A1 (en) | 2019-04-04 |
| JP2023134541A (ja) | 2023-09-27 |
| US11939306B2 (en) | 2024-03-26 |
| CN117209444A (zh) | 2023-12-12 |
| US20240182433A1 (en) | 2024-06-06 |
| WO2019067678A1 (en) | 2019-04-04 |
| US20210380544A1 (en) | 2021-12-09 |
| WO2019061324A1 (en) | 2019-04-04 |
| AU2018341583B2 (en) | 2024-04-04 |
| EA202090500A1 (ru) | 2020-11-03 |
| KR20200060402A (ko) | 2020-05-29 |
| BR112020006137A2 (pt) | 2020-10-13 |
| US20230167077A1 (en) | 2023-06-01 |
| US11643401B2 (en) | 2023-05-09 |
| CN111163772A (zh) | 2020-05-15 |
| MY201378A (en) | 2024-02-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL315814A (en) | Crystalline forms of immunomodulators | |
| JP2022176979A5 (https=) | ||
| IL318981A (en) | Method for preparing crystalline forms of 1,2,4-oxadiazole-3-methyl-1,2-dione | |
| US9309210B2 (en) | Crystalline form of cabazitaxel and process for preparing the same | |
| EP2785701B1 (en) | Crystalline form of carbazitaxel and process for preparation thereof | |
| JP2021501127A5 (https=) | ||
| JP6554617B2 (ja) | １−（５−（２，４−ジフルオロフェニル）−１−（（３−フルオロフェニル）スルホニル）−４−メトキシ−１ｈ−ピロール−３−イル）−ｎ−メチルメタンアミン塩の新規な結晶形 | |
| ES2641299T3 (es) | (1R,4R)-6'-fluor-N,N-dimetil-4-fenil-4',9'-dihidro-3'H-espiro[ciclohexano-1,1'-pirano[3,4,b]indol]-4-amina cristalina | |
| JP2020536872A5 (https=) | ||
| CN112469717B (zh) | 用于纯化艾沙康唑鎓硫酸盐的方法 | |
| HK1205505A1 (en) | A method of preparing a highly pure potassium salt of azilsartan medoxomil | |
| WO2015011659A1 (en) | Crystalline polymorphic forms of regorafenib and processes for the preparation of polymorph i of regorafenib | |
| CN110612291A (zh) | 2-([1,2,3]三唑-2-基)-苯甲酸衍生物的制备 | |
| JP2019172635A (ja) | アジルサルタン微細結晶の製造方法 | |
| JP2007501274A (ja) | カベルゴリンの多形体 | |
| US10538493B2 (en) | Process for the purification of 1-(4-chlorophenyl)pyrazol-3-ol | |
| JP2020536944A (ja) | ３−（５−フルオロベンゾフラン−３−イル）−４−（５−メチル−５Ｈ−［１，３］ジオキソロ［４，５−ｆ］インドール−７−イル）ピロール−２，５−ジオンの固体形態 | |
| CN100408554C (zh) | 高纯度肼基碳酸甲酯的合成新工艺 | |
| KR101184433B1 (ko) | 결정형 올메사탄 실렉세틸의 제조방법 | |
| JP2017517531A (ja) | ピペリジン−４−カルボチオアミドの製造 | |
| WO2019086434A1 (en) | Process for the synthesis of 2-benzhydryl-3 quinuclidinone | |
| KR20210090225A (ko) | 에피나코나졸의 제조 방법 | |
| EP2283010A1 (en) | Process for preparing intermediate compound for synthesizing an antiulcerant | |
| JP2022542918A5 (https=) | ||
| KR20150127996A (ko) | 실로도신 감마형 결정의 제조방법 |